The antiangiogenic and therapeutic implications of endostatin
Ren, B.; Höti, N.; Rabasseda, X.; Wang, Y-Z.; Wu, M.
Methods and Findings in Experimental and Clinical Pharmacology 25(3): 215-224
2003
ISSN/ISBN: 0379-0355 PMID: 12743627 Document Number: 565049
Angiogenesis plays a vital role in the pathology of cancer; ischemic diseases and chronic inflammation, among other conditions. Endostatin, a newly found protein that is distributed in some parts of the human body, has been demonstrated to have a strong inhibitory role in angiogenesis. It specifically inhibits the proliferation of endothelial cells and induces their apoptosis both in vitro and in vivo. Preclinical research has proven its effective role in the treatment of various experimental tumors in rodents. Although endostatin therapy has entered phase II clinical trials in the USA, the exact mechanism and its effects on antiangiogenesis, especially the action on the suppression of endothelial cell proliferation and induction of apoptosis, remain unclear: The treatment modality for malignancies and other angiogenesis-related diseases still requires further analysis.